328 related articles for article (PubMed ID: 29701836)
21. Relationship between tumor markers CEA and CA 15-3, TNM staging, estrogen receptor rate and MIB-1 index in patients with pT1-2 breast cancer.
Lumachi F; Basso SM; Brandes AA; Pagano D; Ermani M
Anticancer Res; 2004; 24(5B):3221-4. PubMed ID: 15510614
[TBL] [Abstract][Full Text] [Related]
22. Nipple discharge of CA15-3, CA125, CEA and TSGF as a new biomarker panel for breast cancer.
Wang G; Qin Y; Zhang J; Zhao J; Liang Y; Zhang Z; Qin M; Sun Y
Int J Mol Sci; 2014 May; 15(6):9546-65. PubMed ID: 24879526
[TBL] [Abstract][Full Text] [Related]
23. Circulating cell-free DNA integrity as a diagnostic and prognostic marker for breast and prostate cancers.
Arko-Boham B; Aryee NA; Blay RM; Owusu EDA; Tagoe EA; Doris Shackie ES; Debrah AB; Adu-Aryee NA
Cancer Genet; 2019 Jun; 235-236():65-71. PubMed ID: 31105051
[TBL] [Abstract][Full Text] [Related]
24. Prognostic significance of serum Her2/neu, BCL2, CA15-3 and CEA in breast cancer patients: a short follow-up.
Samy N; Ragab HM; El Maksoud NA; Shaalan M
Cancer Biomark; 2010; 6(2):63-72. PubMed ID: 20571232
[TBL] [Abstract][Full Text] [Related]
25. Plasma cell-free DNA chromosomal instability analysis by low-pass whole-genome sequencing to monitor breast cancer relapse.
Zhou H; Wang XJ; Jiang X; Qian Z; Chen T; Hu Y; Chen ZH; Gao Y; Wang R; Ye WW; Cao WM
Breast Cancer Res Treat; 2019 Nov; 178(1):63-73. PubMed ID: 31364001
[TBL] [Abstract][Full Text] [Related]
26. Combining the tumor abnormal protein test with tests for carcinoembryonic antigens, cancer antigen 15-3, and/or cancer antigen 125 significantly increased their diagnostic sensitivity for breast cancer.
Chen R; Jiang C; Zhu Q; You S; Li Y; Li S; Ding L; Meng H; Yang Y; Zha X; Wang J
Medicine (Baltimore); 2020 Jul; 99(29):e21231. PubMed ID: 32702897
[TBL] [Abstract][Full Text] [Related]
27. Serum levels of CEA and CA15-3 in different molecular subtypes and prognostic value in Chinese breast cancer.
Wu SG; He ZY; Zhou J; Sun JY; Li FY; Lin Q; Guo L; Lin HX
Breast; 2014 Feb; 23(1):88-93. PubMed ID: 24291374
[TBL] [Abstract][Full Text] [Related]
28. FTO, PIK3CB serve as potential markers to complement CEA and CA15-3 for the diagnosis of breast cancer.
Mi J; Zhang H; Cao W; Yuan C
Medicine (Baltimore); 2023 Oct; 102(42):e35361. PubMed ID: 37861518
[TBL] [Abstract][Full Text] [Related]
29. Serum and Saliva Levels of Cancer Antigen 15-3, Carcinoembryonic Antigen, Estradiol, Vaspin, and Obestatin as Biomarkers for the Diagnosis of Breast Cancer in Postmenopausal Women.
Farahani H; Amri J; Alaee M; Mohaghegh F; Rafiee M
Lab Med; 2020 Nov; 51(6):620-627. PubMed ID: 32537654
[TBL] [Abstract][Full Text] [Related]
30. [Serum concentration of selected neoplasm markers: CA15-3, TPS and CEA in women with diagnosed breast benign disease].
Kochańska-Dziurowicz A; Pasich R; Stanjek A; Gaweł-Szostek V; Jankowski T
Ginekol Pol; 2000 Sep; 71(9):1139-43. PubMed ID: 11082991
[TBL] [Abstract][Full Text] [Related]
31. Association of Preoperative Serum Levels of CEA and CA15-3 with Molecular Subtypes of Breast Cancer.
Zhao W; Li X; Wang W; Chen B; Wang L; Zhang N; Wang Z; Yang Q
Dis Markers; 2021; 2021():5529106. PubMed ID: 34621407
[TBL] [Abstract][Full Text] [Related]
32. Combination of Neutrophil-to-Lymphocyte Ratio and Red Cell Distribution Width With Serum Tumor Markers for the Differential Diagnosis of Breast Cancer and its Association With Pathological Features and Molecular Types.
Zou H; Liu SH; Yang R; Wu XJ; Cao YP; Huang HF
Clin Breast Cancer; 2022 Jun; 22(4):e526-e535. PubMed ID: 34963613
[TBL] [Abstract][Full Text] [Related]
33. Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases.
Nicolini A; Tartarelli G; Carpi A; Metelli MR; Ferrari P; Anselmi L; Conte M; Berti P; Miccoli P
BMC Cancer; 2006 Nov; 6():269. PubMed ID: 17116247
[TBL] [Abstract][Full Text] [Related]
34. Combined measurement of serum sialyl Lewis X with serum CA15-3 in breast cancer patients.
Kurebayashi J; Nomura T; Hirono M; Okubo S; Udagawa K; Shiiki S; Ikeda M; Nakashima K; Tanaka K; Sonoo H
Jpn J Clin Oncol; 2006 Mar; 36(3):150-3. PubMed ID: 16520359
[TBL] [Abstract][Full Text] [Related]
35. Serum Human Epididymis Protein-4 (HE4) - A novel Approach to Differentiate Malignant Frombenign Breast Tumors.
Sai Baba KSS; Rehman MA; Pradeep Kumar J; Fatima M; Raju GSN; Uppin SG; Mohammed N
Asian Pac J Cancer Prev; 2021 Aug; 22(8):2509-2507. PubMed ID: 34452565
[TBL] [Abstract][Full Text] [Related]
36. Vitronectin: a promising breast cancer serum biomarker for early diagnosis of breast cancer in patients.
Hao W; Zhang X; Xiu B; Yang X; Hu S; Liu Z; Duan C; Jin S; Ying X; Zhao Y; Han X; Hao X; Fan Y; Johnson H; Meng D; Persson JL; Zhang H; Feng X; Huang Y
Tumour Biol; 2016 Jul; 37(7):8909-16. PubMed ID: 26753956
[TBL] [Abstract][Full Text] [Related]
37. Serum microRNA-155 as a potential biomarker to track disease in breast cancer.
Sun Y; Wang M; Lin G; Sun S; Li X; Qi J; Li J
PLoS One; 2012; 7(10):e47003. PubMed ID: 23071695
[TBL] [Abstract][Full Text] [Related]
38. Combined detection of CA15-3, CEA, and SF in serum and tissue of canine mammary gland tumor patients.
Fan Y; Ren X; Liu X; Shi D; Xu E; Wang S; Liu Y
Sci Rep; 2021 Mar; 11(1):6651. PubMed ID: 33758208
[TBL] [Abstract][Full Text] [Related]
39. Clinical performance of LOCI™-based tumor marker assays for tumor markers CA 15-3, CA 125, CEA, CA 19-9 and AFP in gynecological cancers.
Dolscheid-Pommerich RC; Keyver-Paik M; Hecking T; Kuhn W; Hartmann G; Stoffel-Wagner B; Holdenrieder S
Tumour Biol; 2017 Oct; 39(10):1010428317730246. PubMed ID: 29034816
[TBL] [Abstract][Full Text] [Related]
40. The diagnostic value of CA 27-29, CA 15-3, mucin-like carcinoma antigen, carcinoembryonic antigen and CA 19-9 in breast and gastrointestinal malignancies.
Frenette PS; Thirlwell MP; Trudeau M; Thomson DM; Joseph L; Shuster JS
Tumour Biol; 1994; 15(5):247-54. PubMed ID: 7991985
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
